Showing results (891-900 of 1,033) with videos related to

Sort By:
Pageof 104
The Lancet. Respiratory Medicine|June 11, 2018
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm studyMargaret Rosenfeld, Claire E Wainwright, Mark Higgins, et al.
The Lancet. Respiratory Medicine|June 20, 2018
The heterogeneity of chronic cough: a case for endotypes of cough hypersensitivityStuart B Mazzone, Kian Fan Chung, Lorcan McGarvey
The Lancet. Respiratory Medicine|May 25, 2019
Aligning use of intensive care with patient values in the USA: past, present, and futureAlison E Turnbull, Gabriel T Bosslet, Erin K Kross
The Lancet. Respiratory Medicine|May 13, 2019
Paediatric tuberculosis transmission outside the household: challenging historical paradigms to inform future public health strategiesLeonardo Martinez, Nathan C Lo, Olivia Cords, et al.
The Lancet. Respiratory Medicine|March 13, 2022
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysisDavies Adeloye, Peige Song, Yajie Zhu, et al.
The Lancet. Respiratory Medicine|March 5, 2022
The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS studyMonica Kraft, Matthew Richardson, Brian Hallmark, et al.
The Lancet. Respiratory Medicine|January 30, 2021
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trialDean A Fennell, Amy King, Seid Mohammed, et al.
The Lancet. Respiratory Medicine|September 14, 2019
Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trialNatalie Walker, Varsha Parag, Marjolein Verbiest, et al.
The Lancet. Respiratory Medicine|August 17, 2019
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b studySteven D Nathan, Jürgen Behr, Harold R Collard, et al.
The Lancet. Respiratory Medicine|August 29, 2018
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trialDongsheng Yue, Shidong Xu, Qun Wang, et al.
Pageof 104